Nektar Therapeutics NKTR

NKTR Company Overview

Nektar Therapeutics is a U.S.-based biopharmaceutical company focused on the research and development of immunology and oncology therapies. The company primarily develops biologic medicines that leverage cytokine biology and polymer conjugate technology to modulate immune system activity. Nektar has historically operated in the biotechnology and specialty pharmaceuticals industries, with a strategic emphasis on autoimmune diseases, chronic inflammatory disorders, and cancer immunotherapy. Its revenue sources have included collaboration agreements, licensing arrangements, milestone payments, and, historically, royalties from partnered drug products.

The company was founded in 1990 and is headquartered in San Francisco, California. Nektar initially built its business around proprietary polyethylene glycol (PEG) conjugation technologies designed to improve the pharmacological properties of therapeutic compounds. Over time, the company transitioned from a platform and royalty-focused model toward internally developed immunology programs. Its strategic positioning has centered on cytokine engineering and immune modulation, particularly through programs intended to selectively activate immune pathways while limiting systemic toxicity associated with conventional cytokine therapies.